The Application of Target Controlled Infusion of Etomidate Combined With Propofol in the Maintenance of Anesthesia During Brain Surgeries
Information source: Henan Provincial Hospital
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Target Controlled Infusion; General Anesthesia
Intervention: propofol (Drug); etomidate (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Henan Provincial Hospital
Summary
To explore the application of target controlled infusion of etomidate combined with propofol
in the maintenance of anesthesia during brain surgeries.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Heart rateBlood pressure Concentration of cortisol
Secondary outcome: Use of vasoactive agentThe time from stop of remifentanil to awake Severity of agitation Postoperative nausea and vomiting Dose of etomidate and propofol Intraoperative awareness Expense of anesthetics Allergic reaction
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Aged between 60 and 80 years Brain surgeries Body weight is between 45 to 75 kg and
body mass index is no more than 30 kg/m2 American Society of Anesthesiology (ASA)
Physical Status: Ⅰ or Ⅱ Expected operation duration is between 3 and 5 h Signed
informed consent form
Exclusion Criteria:
- Serious cardiac, cerebral(acute stroke, uncontrolled seizure, sever dementia), liver,
kidney, lung, endocrine disease or sepsis History of general anesthesia within 24 h
before the operation Long use of hormone or history of adrenal suppression
Hyperlipidaemia Long use of psychotropic substances Systolic pressure is still under
90 mm Hg after twice given of vasopressor agent Suspected abuse of narcotic analgesia
Patients need to use neuromuscular blocking drugs (except intubation) Allergy to
trial drug or other contraindication Pregnant or breast-feeding women Attendance of
other trial past 30 days
Locations and Contacts
Additional Information
Starting date: October 2014
Last updated: June 24, 2014
|